| Autor: |
Storr M; Center of Endoscopy, 82319 Starnberg, Germany.; Medical Clinic II, Ludwig-Maximilians-University, 81377 Munich, Germany., Weigmann H; Consumer Health Care, Sanofi Germany, 65926 Frankfurt, Germany., Landes S; Consumer Health Care, Sanofi Germany, 65926 Frankfurt, Germany., Michel MC; Department of Pharmacology, University Medical Center, Johannes Gutenberg University, 55131 Mainz, Germany. |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of clinical medicine [J Clin Med] 2022 Oct 28; Vol. 11 (21). Date of Electronic Publication: 2022 Oct 28. |
| DOI: |
10.3390/jcm11216361 |
| Abstrakt: |
Functional gastrointestinal disorders (FGIDs), including irritable bowel syndrome (IBS), are frequently handled by self-management with over-the-counter (OTC) products such as hyoscine butylbromide (HBB), alone or in combination with paracetamol, and natural products such as peppermint oil. To obtain real-world information, we have performed an anonymous pharmacy-based patient survey among 1686 users of HBB, HBB + paracetamol, and peppermint oil. Based on the distinct but overlapping indications for the three OTC products, multiple logistic regression was applied to compare them in users reporting gastrointestinal cramps and pain, bloating, flatulence, or IBS as cardinal symptoms. All three treatments reduced symptoms and associated impairments of work/daily chores, leisure activities, and sleep by approximately 50%. Based on the four cardinal symptoms and the four dependent continuous variables of interest (change in intensity of symptoms and of the three impairment domains) a total of 16 logistic regression models were applied. HBB, HBB + paracetamol, and peppermint oil had similar reported overall effectiveness in those models. Gender, age, baseline symptom severity, and impairment in one of three domains had small and inconsistent effects on perceived treatment success. We provide evidence that HBB, HBB + paracetamol, and peppermint oil have comparable effectiveness in their approved indications under real-world conditions in an OTC setting. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
